Transfusion-associated AIDS has become a major health problem as clearly shown by serologic evidence in the general public and by transmission of the disease to chimpanzees with plasma from AIDS patients. The characterization of idiotypic determinants and the generation of anti-idiotypic reagents have provided ppowerful tools with which to analyze and modulate a given immune response. The idiotype network developed during the course of an immune response provides conceptual insight into the host response to a given antigen. It is proposed to analyze the idiotype network initiated by a host in response to a human T-cell lymphotropic virus type III (HTLV-III) infection or immunization with HTLV-III. The idiotypes that are expressed on human, chimpanzee and mouse antibodies to the envelope glycoproteins, gp 120 and gp 41, of HTLV-III will be examined. The expression of these idiotypic determinants on antibodies to gp 120 and gp 41 produced in naturally infected and immunized individuals will be analyzed. The identification of a major common idiotype(s) in human sera positive for anti-gp 120 and anti-gp 41 will be used to detect potential variable region antibody gene differences among AIDS diagnoses individuals and in blood donors containing antibody but having no disease. The epitopes associated with gp 120 and gp 41 and with synthetic gp 120 and gp 41 peptides will be identified. In addition, we will examine the use of anti-idiotypic antibodies for an effective safe vaccine. The results of these experiments will give insight into whether idiotype networks, expression of particular idiotypes or both are important in the host's response to HTLV-III. These anti-idiotype reagents may also identify serologic markers as indicators of infectivity.

Project Start
1986-04-01
Project End
1989-03-31
Budget Start
1987-04-01
Budget End
1988-03-31
Support Year
2
Fiscal Year
1987
Total Cost
Indirect Cost
Name
Southwest Foundation for Biomedical Research
Department
Type
DUNS #
City
San Antonio
State
TX
Country
United States
Zip Code
78245
GarcĂ­a, C C; Topisirovic, I; Djavani, M et al. (2010) An antiviral disulfide compound blocks interaction between arenavirus Z protein and cellular promyelocytic leukemia protein. Biochem Biophys Res Commun 393:625-30
Zhou, E M; Lohman, K L; Kennedy, R C (1990) Administration of noninternal image monoclonal anti-idiotypic antibodies induces idiotype-restricted responses specific for human immunodeficiency virus envelope glycoprotein epitopes. Virology 174:9-17
Zhou, E M; Kennedy, R C (1989) Strategies for developing vaccines against acquired immunodeficiency syndrome. Biochim Biophys Acta 989:301-13
Cauda, R; Tumbarello, M; Ortona, L et al. (1988) Inhibition of normal human natural killer cell activity by human immunodeficiency virus synthetic transmembrane peptides. Cell Immunol 115:57-65
Kennedy, R C; Chanh, T C; Allan, J S et al. (1988) Overview on the use of synthetic peptides in human immunodeficiency virus infection. Adv Biotechnol Processes 10:149-72
Kennedy, R C; Chanh, T C (1988) Perspectives on developing anti-idiotype-based vaccines for controlling HIV infection. AIDS 2 Suppl 1:S119-27
Kennedy, R C; Dreesman, G R; Chanh, T C et al. (1987) Use of a resin-bound synthetic peptide for identifying a neutralizing antigenic determinant associated with the human immunodeficiency virus envelope. J Biol Chem 262:5769-74
Zhou, E M; Chanh, T C; Dreesman, G R et al. (1987) Immune response to human immunodeficiency virus. In vivo administration of anti-idiotype induces an anti-gp160 response specific for a synthetic peptide. J Immunol 139:2950-6
Chanh, T C; Dreesman, G R; Kennedy, R C (1987) Monoclonal anti-idiotypic antibody mimics the CD4 receptor and binds human immunodeficiency virus. Proc Natl Acad Sci U S A 84:3891-5
Dalgleish, A G; Thomson, B J; Chanh, T C et al. (1987) Neutralisation of HIV isolates by anti-idiotypic antibodies which mimic the T4 (CD4) epitope: a potential AIDS vaccine. Lancet 2:1047-50

Showing the most recent 10 out of 14 publications